Active Biotech (STO:ACTI) AB Interim Report January-September 2008

Active Biotech (STO:ACTI) - Laquinimod -- positive data presented from extension study

- 57-57 -- Clinical Phase II/III trial to commence in 2009

- RhuDex® -- Additional preclinical tests under way

- ANYARA -- Phase III study proceeding as planned

- TASQ -- Phase II study proceeding as planned

- Net sales SEK 8.8 M (8.7)

- Operating loss SEK 167.0 M (loss: 147.8 )

- Loss after tax SEK 162.0 M (loss: 152.0)

- Loss per share for the period amounted to SEK 3.30 (loss: 3.30)
For further information, please contact: Tomas Leanderson President and CEO Tel: +46 (0)46-19 20 95

Göran Forsberg VP Investor Relations & Business Development Tel: +46 (0)46-19 11 54

Hans Kolam CFO Tel: +46 (0)46-19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227) PO Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



LINK: http://hugin.info/1002/R/1269607/280811.pdf

Active Biotech

http://www.activebiotech.com/

ISIN: SE0001137985

Stock Identifier: XOME.ACTI

US: ACTI.ST